Global

‡ In these countries please contact our distributor

How does RENASYS tNPWT compare to V.A.C.™

This information is intended for HCPs in the US.
Please consult your local Smith + Nephew representative for further details on products available in your market. 

Comparing RENASYS tNPWT to V.A.C.™

A large-scale retrospective study compared RENASYS tNPWT to V.A.C.™ and found them largely comparable in terms of clinical performance and patient experience.1

 

  • 94% of patients treated with RENASYS tNPWT achieved their treatment goal, compared to 90% with V.A.C.™1

  • Treatment with RENASYS tNPWT resulted in a 65% wound area reduction, compared to 64% with V.A.C.™1

  • RENASYS tNPWT achieved a weekly wound reduction rate of 9.7%, compared to 9.4% with V.A.C.™1

  • Both devices reached the treatment objectives in 8 weeks (median).1

Read: Key evidence comparing RENASYS tNPWT to V.A.C™

Comparing the cost of tNPWT pumps

According to a 2019 report by the ECRI Institute, use of the RENASYS System resulted in a 70% reduction in the cost of purchasing tNPWT pumps over 10 years. Calculated from an estimated service life and service costs.

Contact us to find out more

 

Comparing RENASYS AB with ABTHERA™

In an in vivo study, RENASYS AB was shown to be as effective as ABTHERA™

  • Both devices are capable of efficiently managing large volumes of fluid2
  • Fluid removal over time was comparable2
  • Both devices left similar volumes of residue2

Read the latest evidence comparing RENASYS AB to ABTHERA

Helping you get CLOSER TO ZERO delay in wound healing.1 

Important Safety Information

The information herein is intended for healthcare professionals. RENASYS is contraindicated in the presence of untreated osteomyelitis, exposed arteries/veins/organs/nerves, necrotic tissue with eschar present, malignancy in the wound, non-enteric and unexplored fistulas, and exposed anastomotic sites. Excessive bleeding is a serious risk associated with the application of suction to wounds, which may result in death or serious injury. For full product and safety information, please see the Instructions for Use.

All trademarks acknowledged.

References:
1. Hurd T, Rossington A, Trueman P, Smith J. A Retrospective Comparison of the Performance of Two Negative Pressure Wound Therapy Systems in the Management of Wounds of Mixed Etiology. Advances in Wound Care. 2017;6(1):33-37.
2. SELECTPlus Technology SNAPSHOT: Rapid Access Market Intelligence for Healthcare Decision Makers (Negative Pressure Wound Therapy Systems). ECRI Institute, 2019.
3. Dunn R, Tessier H, Hammond V, Webster I. Ability of Commercial NPWT Systems to Manage Fluid in an Experimental Open Abdomen Study. Paper presented at: WSACS; 2017; Canada.
Important Safety Information

 

The information herein is intended for healthcare professionals. RENASYS is contraindicated in the presence of untreated osteomyelitis, exposed arteries/veins/organs/nerves, necrotic tissue with eschar present, malignancy in the wound, non-enteric and unexplored fistulas, and exposed anastomotic sites. Excessive bleeding is a serious risk associated with the application of suction to wounds, which may result in death or serious injury. For full product and safety information, please see the Instructions for Use.

RENASYS◊  GO
Post-Acute NPWT Solution in the United States

Order your RENASYS GO pump in the US through Rotech Healthcare, Inc.

Download now

Intended for HCPs in the US only